SLS Client Felicis Ventures Joins Recursion Pharmaceuticals’ $239MM Round

Silicon Legal represented Felicis Ventures as they joined Recursion Pharmaceuticals’ $239 million Series D financing.

Recursion Pharmaceuticals, a clinical-stage biotechnology company, combines experimental biology, automation, and artificial intelligence to discover treatments at the cellular level. The financing was led by Leaps by Bayer and included investments from, in addition to Felicis Ventures, Casdin Capital, Catalio Capital Management, Laurion Capital Management, Samsara BioCapital, Baillie Gifford, Mubadala, DCVC, Lux Capital, Obvious Ventures, EPIC Ventures, Two Sigma Ventures, Advantage Capital and Intermountain Ventures.

The Silicon Legal client team included Gaurav Mathur, Heidi Walas, Natasha Hsieh, Sarah Boulden, Mike Perez, Noah Driggs and Lynn Stahli.

Back to Client News